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Statement of the Problem 
 
While significant progress has been made in the reduction of tobacco use in the 
United States over the last decade (Centers for Disease Control and Prevention 
[CDC], 2018b) the smoking prevalence rates among the socially and economically 
disadvantaged populations remain high (CDC, 2018b).  As a result, these 
vulnerable populations carry a disproportionate economic, morbidity, and 
mortality burden that is related to tobacco use (CDC, 2018b; Flocke, Hoffman, 
Park, Birkby; Trapl et al., 2017).  There is cost-effective, and evidence-based 
treatment available for tobacco use dependence (Fiore et al., 2008; Stead, 
Koilpillai, Fanshawe, and Lancaster, 2016), but aspects of that treatment are not 
being delivered consistently to this population (Roberts, Kerr, & Smith, 2013; 
Twyman, Bonevski, Paul, and Bryant, 2014). The purpose of this research is to 
improve access to evidence-based behavioral health referrals and pharmacotherapy 
for tobacco use dependence treatment for the vulnerable population served by the 




With the inhalation of tobacco smoke, the body is exposed to more than 7000 toxic 
chemicals and at least 70 carcinogens (American Cancer Society [ACS], 2017).  
Some of the chemicals in and produced by burning tobacco and its additives 
include nicotine, hydrogen cyanide, formaldehyde, lead, arsenic, ammonia, 
radioactive uranium, benzene, carbon monoxide, and nitrosamines (United States 
Department of Health and Human Services [USDHHS], 2014, ACS, 2017).    
   
According to the American Lung Association (2019) State of Tobacco 
Control Report, seven out of ten smokers wish to quit.  Only 4 to 7 % of individuals 
who attempt to stop smoking can do it “cold turkey” (Fiore et al., 2008). Getting 
support from the healthcare provider, which includes counseling and medication, 
doubles the chances for a successful quit attempt (ACS, 2018).  For most smokers, 
quitting is more than just willpower.  On average, smokers may attempt to quit 6-
11 times before they succeed (ACS, 2018).    
A disproportionate burden in the vulnerable population.  Despite the 
progress in reducing smoking prevalence among the general population within the 
United States (CDC, 2018), there exist significant healthcare disparities related to 
  
 
tobacco use within certain populations in the United States (CDC, 2018b).  Health 
equity is defined in public health as the opportunity for all to “reach their full health 
potential” (Whitehead & Dahlgren, 2006).  According to Whitehead & Dahlgren 
(2006), no one should be prevented from achieving this potential because of their 
social position or social circumstance.  Health equity as it relates to tobacco use 
prevention and control is the opportunity for everyone to live a healthy, tobacco-
free life, regardless of their level of education, sexual orientation, the job they have, 
gender identity, whether they have a disability, or their race (CDC, 2015).  Best 
Practices (Whitehead & Dhalgren, 2006) recommends that to further reduce 
overall tobacco use and second-hand exposure, attention to reducing tobacco use 
and second-hand exposure in the population groups that bear the greatest burden 
of tobacco use will help to reduce those disparities.  
Prevalence and factors related to tobacco use in vulnerable 
populations.  In general, the smoking prevalence rates are higher among males, 
those who are aged 25-64 years, individuals with less education, American 
Indians/Alaska Natives, individuals of multiple races, uninsured, or insured 
through Medicaid, individuals living below the poverty line, those who have a 
disability, and individuals who are part of the lesbian, gay, bisexual, or transgender 
community, and those who are living in the Midwest or the South (CDC, 2018b).    
In 2016, the estimated percentage of adults (18 years and older) who are currently 
smoking is at 15.5% (37.8 million), in striking contrast to prevalence rates with 
vulnerable populations (Jamal et al, 2018According to Jamal et al., (2018), the 
prevalence rates in the U.S. (2016) as it relates to race/ethnicity were:  American 
Indians and Alaskan Natives-31.8%, Asians (non-Hispanic)-9.0%, Blacks (non-
Hispanic)-16.5%, Hispanics-10.7%, Multiple Races (non-Hispanic)-25.2%, and 
Whites (non-Hispanic)-16.6%.   
According to the CDC’s Morbidity and Mortality Weekly Report (2015), 
adults in the United States who are on Medicaid or are uninsured engage in tobacco 
use at a rate of more than double of those adults who have either private health 
insurance or are on Medicare. In comparison, only 12.9% of adults who have 
private insurance smoke, and only 12.5% of Medicare recipients currently smoke 
(CDC, 2015).   According to the 2014 National Health Interview Survey (NHIS), 
29.1% of Medicaid patients smoke, and 27.95 % of uninsured patients currently 
smoke.   
Health Risks Associated with Tobacco Use.  There is no safe way to use 
tobacco products. (ACS, 2017).  About 50% of those smokers, if they continue to 
smoke, will die because of their tobacco use, and they will die younger than non-
smokers (ACS, 2017).  Tobacco use shortens the lives of male smokers by 12 
years, and female smokers by 11 years (ACS, 2017).   The American Cancer 
Society (2017) reports that the use of tobacco increases cancer risk, and accounts 
for thirty (30%) of all cancer deaths.  Smoking tobacco is responsible for eighty 
  
 
(80%) of all lung cancer deaths in the United States.  While the risk for lung cancer 
is significant and especially hard to treat, the risk for other cancers is also high (i.e. 
mouth, larynx, pharynx, esophagus, kidney, cervix, liver, bladder, pancreas, 
stomach, colon, and myeloid leukemia).  Also, the risks for lung cancer and other 
related diseases are increased for those individuals who are exposed to second-
hand smoke (ACS, 2017).  Cigar smokers are four to ten times more likely to die 
secondary to cancers of the throat, larynx, esophagus, and mouth than individuals 
who do not smoke (ACS, 2017).   
Economic costs attributable to tobacco use.  Because of the higher 
smoking prevalence rates among vulnerable populations, there is also a significant 
economic impact that is attributable to tobacco use.  The global cost for tobacco 
use accounted for nearly 2% of the world’s gross domestic product in 2012, or 
$1,436 billion US dollars, according to the World Health Organization (WHO) 
(Boyles, 2017, Goodchild, 2017).  A global economic impact analysis was 
completed by WHO and the World Bank (Goodchild, 2017).  That study measured 
both the direct cost of smoking (i.e. hospital admissions and treatment) and the 
indirect costs using the validated human capital methods (HCM) which calculates 
the value of human capital loss due to death and illness.  Global working years lost 
due to smoking-related illness and death totaled 26.8 million.  The indirect costs 
of smoking-related diseases were estimated to be $1,014 billion (US dollars) with 
disability accounting for $357 billion and death accounting for $939 billion 
(Goodchild, 2017).   
Smoking-related costs totaled an estimated 3% of the gross domestic 
product of the United States (Goodchild, 2017).  For every smoking attributed 
death, there are at least thirty (30) people that live with a smoking-related disease.  
Smoking-related illness in the United States results in more than $300 billion per 
year, which is nearly $170 billion in direct medical care for adults and more than 
$256 billion in lost productivity (ACS, 2018). 
Positive health and economic impact of smoking cessation.  According 
to the National Cancer Institute (NCI) Smokefree.gov website (2019), within hours 
of quitting tobacco use, the individual’s blood pressure and heart rate decrease, 
and the risk of heart attack is reduced.  Risks for hearing loss, and overall vision is 
decreased, and night vision is improved.  The risk for premature aging and 
excessive wrinkling of the skin is reduced.  Risks for the formation of harmful 
blood clots is reduced.  The individual can expect a brighter smile, less shortness 
of breath with exertion, stronger bones, reduction of serum cholesterol, and 
normalization of white blood cells following smoking cessation (National Cancer 
Institute [NCI], 2019).  For an extensive list of positive health outcomes following 
smoking cessation (See Appendix A for a complete list of positive health 
outcomes) (WHO, 2014.).   
  
 
Tobacco use prevention and control activities are public health’s “best buy” 
(CDC, 2018a).  These activities are considered comprehensive and have 
demonstrated that they reduce the number of people who currently smoke, and 
therefore reduce tobacco-related health care costs and hospitalizations by up to $55 
for every dollar spent on prevention (CDC, 2018a).   
Cost-effective and evidence-based treatment recommended.  The 
Department of Health and Human Services, Public Health Service published 
updated clinical practice guidelines in Treating Tobacco Use and Dependence 
(Fiore et al., 2008) that provided evidence-based and cost-effective treatment (See 
Appendix B for the 10 Key Recommendations).  As part of those guidelines, they 
utilized the conceptual framework of motivational interviewing and recommended 
the 5A’s (See Appendix C) and 5 R’s (See Appendix D) models to be used by 
healthcare providers when treating tobacco dependence.  In 2014, the United States 
Preventive Services Task Force reiterated the guidelines as “A” recommendations 
for the reduction of tobacco use (See Appendix E).  Implementation of these 
recommendations is generally incorporated in the tobacco use prevention and 
control activities at the global, national, and state-level (WHO, 2017, USDHHS, 
2013, Chung, Lavender and Bayakly, 2016).  In 2018, Barua, and Rigotti et al., 
published the American Academy of Cardiology Expert Consensus Decision 
Pathway on Tobacco Cessation Treatment (Appendix F) providing their 
recommendations for treatment of cardiac patients that are currently using tobacco 
that also reflect similar recommendations as the original guidelines. 
Global and national approach to the tobacco use epidemic.  Tobacco 
use remains the world’s leading cause of premature mortality and smoking-related 
morbidity (WHO, 2015).  The American Cancer Society web site (Drope et al., 
2018) estimates that there are currently one billion smokers in the world.  Tobacco 
use is the leading cause of preventable mortality because of the association of 
smoking-related diseases that result in nearly six million deaths per year (WHO, 
2015).  To gain some perspective, the combined mortality annually from 
tuberculosis, human immunodeficiency virus (HIV), and malaria are less than the 
tobacco-related deaths per year (WHO, 2011).  Based on current projections, 
tobacco use is expected to be responsible for eight million deaths or 10% of global 
deaths by 2030.  The strong association with tobacco use and lower socioeconomic 
status continues to generate increasing health disparities at both the global and 
national levels (Van Schayck et al., 2017).  To confront this epidemic, the United 
Nations General Assembly in 2011 adopted a declaration that committed the 
members to a 25% reduction in premature mortality from non-communicable 
diseases by 2025, which includes a 30% reduction in smoking prevalence (United 
Nations, 2011).  Tobacco control policies generated by the World Health 
Organization (WHO, 2015), an agency of the United Nations, as developed by the 
Framework Convention on Tobacco Control (FCTC) has been successful in 
  
 
reducing smoking prevalence.  Article 14 of the FCTC addresses the treatment of 
tobacco dependence and insists that cessation support is an essential component of 
treatment and works synergistically with the other tobacco control measures 
(WHO, 2015).  While many of the public health efforts recommended by WHO 
has been successful in preventing individuals from commencing the use of 
tobacco, many individuals who are addicted to the nicotine in tobacco that will 
need the assistance of a healthcare provider to stop smoking tobacco (Van Schayck 
et al., 2017).  WHO (2015) has suggested that primary care is the most suitable 
healthcare setting for providing advice and treatment for smoking cessation.  
According to Raw, Mackay, and Reddy (2016), only 15% of the world’s 
population has access to this smoking cessation support.  According to WHO 
FCTC: High Level of Ratification, Low Level of Full Implementation Report 
(WHO Regional Office for Europe, 2018), the WHO Framework Convention on 
Tobacco Control (FCTC) is a legally binding treaty for cost-effective tobacco 
control has nearly 50 countries (out of 53) who have committed to implementation 
but still have not fully implemented the policies that they have agreed to in the 
FCTC.    
Significant strides have been made in the reduction of smoking and 
tobacco use within the United States (CDC, 2018b).  According to the CDC 
(2018b), cigarette smoking among U.S. adults (aged 18 years or above) has 
declined from 20.9% in 2005 to 17.9% in 2016.  In 2015, an estimated 52.8 
million adults were former smokers. Of the 36.5 million current adult smokers, 
49.2 percent stopped smoking for a day or more in the preceding year because 
they were trying to quit smoking completely (ALA, 2018, CDC, 2015).  
The findings from the National Health Interview Survey (NHIS) indicate 
that the percentage of adults who have quit smoking increased from 50.8% in 
2005 to 59% in 2016 (CDC, 2018).  According to the CDC (2018b), more 
people are quitting, and those that remain smoking have decreased the number 
of cigarettes smoked.  Cigarette smoking among U.S. adults has been reduced 
by 50% since 1964, according to the CDC (2018b).  While this gradual decline 
is to be celebrated, tobacco use remains the leading cause of preventable 
morbidity and mortality (CDC, 2018b) in the United States.  Smoking-related 
diseases result in premature deaths of more than 480,000 Americans per year 
(CDC, 2018b), or about 1 in 5 deaths (USDHHS, 2014).  For every person who 
dies from tobacco use, there are 30 Americans who suffer from smoking-
attributable diseases (CDC, 2018b).   According to Jamal et al., (2018), more 
males smoke than females, ages 25-64 years constitute the largest group of 
smokers, the lower the education the higher the smoking prevalence, and those 
individuals who live below the poverty level are more likely to smoke.  Jamal 
et al. (2018) report that adults that smoked daily, eighty-seven percent had tried 
their first cigarette by 18 years of age, and ninety-five percent by the age of 21.  
  
 
According to the American Lung Association (2018), nearly 9.3% of high 
school students use tobacco, and 2.3% of middle school students are current 
smokers of tobacco.   
In Healthy People 2020 (USDHHS, 2013), the overall goal regarding 
tobacco use was to reduce illness, disability, and death related to tobacco use 
and secondhand smoke exposure in the United States.  Objective TU-4 sets the 
target at 8% (adult smokers who have successfully stopped smoking within the 
past 6 months to 1 year), and 80% (of adults aged 18 years and older who have 
attempted to stop smoking in the past 12 months) (USDHHS, 2013).  
Healthcare system change objectives included increasing Medicaid coverage 
for nicotine dependency pharmacotherapy that was evidence-based (TU-9).  
The target for increasing tobacco cessation counseling in office-based 
ambulatory care settings (TU-10.1) is 21.1% (% of visits among current tobacco 
users who are adults being seen at office-based ambulatory care settings who 
had tobacco cessation counseling provided or ordered during that visit).  Also, 
the objectives included increasing tobacco cessation counseling in substance 
abuse, and mental health care settings (USDHHS, 2013).   
Georgia and North Central Public Health Districts approach to 
tobacco use.  Based upon updated 2018 data from the CDC’s Behavioral Risk 
Factor Surveillance System (BRFSS), The United Health Foundation (2018) has 
determined that the State of Georgia’s overall smoking prevalence rate is 17.1%.  
According to the 2016 Georgia Tobacco Use Surveillance Report (Chung, 
Lavender, & Bayakly, 2016), the State of Georgia had 1.35 million adult smokers, 
over 10,000 adults in Georgia die from smoking-related diseases per year, and the 
economic costs are staggering with 3.2 billion dollars in lost productivity and 1.8 
billion dollars in healthcare costs attributed to smoking based upon the CDC’s 
Behavioral Risk Factor Surveillance System 2014 data.  Other significant 
conclusions from the 2016 Georgia Adult Disparities in Tobacco Use Report 
(Chung, Lavender & Bayakly, 2016) included:  In Georgia, smoking prevalence is 
highest among non-Hispanic whites (19.3%, or 785,000) followed by Hispanics 
(15.6%, 92,000), and non-Hispanic blacks (14.6%, 201,000) (Chung et al, 2106).  
Smoking cigarettes are 6 times more likely among adults without a high school 
education (31.8%) than with a college education (5.6%).  Adult males (40.7%) that 
do not have a high school education are more likely to smoke in comparison to all 
other groups (Chung et al., 2016).  Approximately 25% of Georgia adults do not 
have any type of health insurance (Chung et al., 2016).  Forty-five (45) percent of 
non-Hispanic white smokers and twenty-nine (29) percent of non-Hispanic Black 
smokers do not have any form of health insurance.  Based upon the 2014 BRFSS 
data, cigarette smoking is higher among individuals who are employed in 
construction (32.2 %), food preparation (31.4%), and transportation and material 
  
 
moving occupations (27.8%) (Chung et al.,2016).  Almost 21% of stroke patients 
in Georgia are current smokers (Chung et al., 2016).  For patients who have had a 
heart attack, 22% were current smokers. And one-fourth (25%) of adults who 
suffer from asthma continue to smoke (Chung, et al., 2016).   According to 
Gvinianidze and Tsereteli (2012), about 72,500 potential years of life were lost in 
Georgia during the year 2008 due to active smoking, with most of the burden being 
related to cancer and cardiovascular diseases. 
The estimated number of adult smokers for the North Central Public Health 
District is 54,000, and the smoking prevalence is 16.8 percent according to the 
2014 BRFSS data (Georgia Department of Health, 2016). The North Central 
Health District is comprised of Baldwin, Bibb, Crawford, Hancock, Houston, 
Jasper, Jones, Monroe, Peach, Putnam, Twiggs, Washington and Wilkinson 
counties (North Central Public Health, 2019).   
FQHC clinics in the U.S. and FQHC study clinics prior approach.  
While tobacco use poses serious health risks for the general population, the density 
of high-risk populations that are treated at FQHC clinics results in a smoking 
prevalence rate of 25.8, an average of 5.2% percentage points (Range, -4.9 to 20.9) 
higher among FQHC clinics (Flocke et al., 2017).    
According to Flocke et al., (2017), Georgia has 23 FQHCs serving a total 
of 156,980 patients, and 36,182 of those patients currently smoke.  This equates to 
an average smoking prevalence rates within FQHC clinics in Georgia at 25.3% 
(Range: 6.0-48.8) in comparison to 22.4% tobacco use in Georgia’s population.    
Before the commencement of the study, an FQHC study clinic smoking 
prevalence report was generated from the electronic health record for 2017 and 6 
months of 2018.  Based on the data provided by FQHC EHR, it is estimated that 
the smoking prevalence rate was 32.5% (K. Arispe [personal communication, 
April 18, 2018]).  These statistics support the premise that the population 
frequently served at the FQHC study clinics are at a higher risk for ongoing 
tobacco abuse without the usual ability to access evidence-based smoking 
cessation treatment secondary to lower socioeconomic status, and lack of 
insurance. 
The FQHC clinics had previously implemented changes in the EHR to 
include prompts on smoking status and desire to quit smoking in response to the 
national guidelines for the treatment of tobacco use dependence.  The support staff 
routinely asks incoming patients a series of evidenced-based questions to 
determine tobacco use status, the level of nicotine dependence (based on the 
frequency of smoking cigarettes), and validate tobacco cessation pharmacotherapy 
listed in current medications.  When the patient is seen by the health care provider, 
and the system identifies the patient as a current smoker, the anticipation is that 
the provider will enter the advice to quit under preventive counseling and whether 
the patient desires to make a quit attempt.  Within the preventive and counseling 
  
 
sections of the electronic health record, several options are provided to select 
evidence-based treatment to facilitate easy documentation of smoking cessation 
treatment.  Informal discussions with healthcare providers before the intervention 
provided valuable information by the identification of barriers perceived by the 
administrative and healthcare providers.  When the higher prevalence rates were 
demonstrated for the administrative and healthcare provider team, there was an 
interdisciplinary organizational effort to work to reduce the smoking prevalence 
rate at the FQHC study clinic and agreement to support the efforts of the principal 
investigator to develop an intervention that may have the potential to increase the 
delivery of evidence-based smoking cessation treatment and indirectly reduce the 
smoking prevalence rate for their vulnerable populations.   
 
Significance of the Problem 
 
Research about smoking cessation treatment is extensive.  Upon careful analysis 
of systematic reviews and meta-analysis studies, national guidelines have been 
generated for tobacco use dependence treatment.  Evidence-based interventions 
were recommended in those guidelines, but subsequent studies demonstrate that 
the translation of those guidelines into clinical practice is not occurring 
consistently.   
The research highlights that the assistance with and arranging for 
behavioral health referrals and smoking cessation pharmacotherapy (as 
recommended by national guidelines) is where the deficiencies remain in the 
delivery of evidence-based smoking cessation treatment.  Additional studies have 
researched factors that impact the full implementation of those guidelines, 
including the lack of education and training, lack of resources, and concerns about 
the cost of the counseling and pharmacotherapy (Colomar et al., 2014; Himelhoch 
et al., 2014; Van Schayck et al., 2017).     
Gaps in the literature included studying the impact of a multicomponent 
intervention (focused educational training and provision of quick reference 
materials) on the referral and prescribing behaviors of healthcare providers in an 
FQHC setting within a southeastern state.   
According to Flocke et al. (2017), the prevalence rates for tobacco use in 
federally qualified healthcare clinics (FQHC) averages 5.2 percentage points 
higher (range -4.9 to 20.9) when compared to the general population of the United 
States.  As an FQHC, the healthcare clinicians at the study clinic have the 
responsibility to provide smoking cessation treatment to its vulnerable 
populations.  They need to address the FQHC study clinics estimated the smoking 
prevalence of 32% (K. Arispe [personal communication April 18, 2018]) to further 
reduce the health disparities that are occurring in their population because of the 
tobacco use epidemic in Middle Georgia.   
  
 
Even a small improvement in smoking cessation referrals and treatment can 
yield substantial improvements in quality of life for those patients who can stop 
smoking.      
 
Purpose Statement 
The purpose of this research is to improve access to evidence-based 
behavioral health referrals and pharmacotherapy for tobacco use dependence 
treatment for the vulnerable population served by the FQHC study clinic 
healthcare clinicians.  The goal of this study is to find a solution for the lack of 
consistent delivery of “Assistance” and “Arrangement” (5 A’s Model) of the U.S 
Public Health Guidelines for Tobacco Use Dependence Treatment (Fiore, et al., 
2008) as it relates to behavioral health referrals and pharmacotherapy for smoking 
cessation.   
Specific aim 1.  To develop a multicomponent intervention for the FQHC 
clinician participants that is based upon the conceptual framework of Kotter’s 
Change Theory (Kotter, 2014) assists in the translation of evidence to clinical 
practice and addresses the identified barriers to implementation of the clinical 
guidelines as it relates to behavioral health referrals and pharmacotherapy.   
Specific aim 2.  Measure the impact of the provision of the 
multicomponent intervention to determine if it has improved the delivery of 
behavioral health referrals and pharmacotherapy by comparing the data before the 
intervention to the data retrieved at eight weeks following the intervention and 
determining if there is a statistical or clinical significance.  Participants will be 
encouraged to utilize the evidence-based 5A’s and 5 R’s Model to deliver smoking 
cessation therapy.  
Specific aim 3.  Measure the percentage of current smokers who have been 
advised to quit that are motivated to make a quit attempt and compare with other 
research studies that have ascertained the percentage of current smokers that wish 
to make a quit attempt.   
Specific aim 4.  Describe the sample characteristics and correlate the 
individual characteristics to improvement in the delivery of behavioral health 
referrals and pharmacotherapy for smoking cessation.   
Clinical Questions 
Clinical question 1.  How does education about smoking cessation and the 
provision of quick reference materials affect referrals to behavioral counseling and 
prescribing smoking cessation pharmacotherapy with healthcare providers at 
federally qualified healthcare centers in one southeastern state within an eight-
week period?  
Clinical question 2. What percentage of Self-Identified Current Smokers 
(SICS) expressed a willingness to attempt quitting?  
  
 
Clinical question 3. What provider characteristics are associated with 
increased smoking cessation referrals/treatment?      
Definitions and Terms 
Federally Qualified Healthcare Center (FQHC) Study Clinic.  
Community-based outpatient clinics that have qualified for specific 
reimbursement systems under Medicare and Medicaid to provide primary care 
services in underserved areas (Health Resources and Services Administration 
[HRSA], 2018). 
Current smoker.  “An adult who has smoked 100 cigarettes in his or her 
lifetime, and who currently smokes cigarettes.” (CDC, 2019). 
Smoking status of the patient.  A designation that is recorded in the 
electronic health record of the FQHC study clinic based upon several questions 
about cigarette smoking as a current smoker, former smoker, never smoked, and 
smoking status unknown.   
Participant.  A healthcare clinician (i.e. MD, DO, NP, PA) providing 
primary care during the designated periods at one of the five participating FQHC 
study clinics and have agreed to voluntarily participate (signed informed consent), 
and who were present at the provider meeting when the intervention occurred.  
Principal Investigator (PI) was not a participant.  
Multi-component intervention [Phase 1].  An intervention comprised of 
an educational presentation on July 25, 2018, provision of a quick reference 
handbook to the participants, and revisions in the electronic health record system 
to facilitate documentation of the qualifying smoking cessation treatment. 
  Pre-Intervention data collection [Phase 2].  Patient data retrieved from a 
retrospective electronic health record review at the FQHC study clinic for 8 weeks 
pre-intervention for each participant.   
Post-Intervention data collection [Phase 3].  Patient data retrieved from 
a retrospective electronic health record review at the FQHC study clinic for 8 
weeks post-intervention for each participant.  
Candidate.  Patients that are identified in the electronic health record as 
current smokers, who have been counseled to quit within the last 24 months, who 
are interested in quitting smoking, and have not been provided quitline or handouts 
in 12 months.  
Compliance.  Data retrieved from retrospective chart review that 
documented any of the following as it relates to behavioral health referrals:  1) 
Healthcare provider counseling for smoking cessation, or 2) Healthcare provider 
referral to mental health clinician for face-to-face or group supportive counseling, 
or 3) Referral to smoking cessation classes, or 4) Referral to the Georgia Tobacco 
Quitline by the provision of telephone numbers or initiating an electronic or fax 
  
 
referral, or 5) Provision of written materials that provided community resources 
for behavioral health for smoking cessation therapy. 
Data retrieved from retrospective chart review that documented any of the 
following prescriptions ordered, recommended, or referred to an entity to which 
they could obtain the following medications or smoking cessation medications 
identified as current medications in the electronic health record for the visit in 
which the patient is seen when deemed eligible:  1)  Bupropion SR (Zyban, 
Wellbutrin); 2) Nicotine gum; 3) Nicotine inhaler; 4) Nicotine Lozenge; 5) 
Nicotine Nasal Spray; 6) Varenicline (Chantix); 7) Or any combination thereof.  
Data retrieved from retrospective chart review that documented the 
following is considered compliance:  1) behavioral health referral or 2) 
pharmacotherapy for smoking cessation or 3) provided either or both.   
Current smokers who expressed a desire to quit.  Self-identified current 
smokers who have expressed a desire to quit smoking or agreed to attempt to quit 
smoking or was provided with a behavioral health referral or pharmacotherapy for 
smoking cessation (implied consent).  
 
Literature Review and Synthesis 
 
The literature review will provide a summary of the clinical practice guidelines 
Treating Tobacco Use and Dependence (Fiore, et al., 2008), the Tobacco Smoking 
Cessation in Adults, Including Pregnant Women: Behavioral and 
Pharmacotherapy Interventions published by the U.S. Preventive Services Task 
Force (2015), and the American College of Cardiology (ACC) Expert Consensus 
Decision Pathway on Tobacco Cessation Treatment (Barua, R. S. and Rigotti, N. 
A., et al., (2018).   Studies demonstrating the efficacy of behavioral counseling and 
pharmacotherapy for smoking cessation (Fiore et al., 2008, Papakadis et al., 2016, 
Piper et al, 2018) will be included in the review.  Studies reviewed suggest primary 
care providers are uniquely positioned to deliver effective tobacco cessation 
treatment with a brief intervention using the 5 A’s and 5 R’s model as 
recommended by Fiore, et al. (2008).  The provision of the evidence-based 
treatment using these models by primary care providers results in higher smoking 
cessation quit rates (Fiore et al., 2008; Stead, Koilpillai, Fanshawe, and Lancaster, 
2014).  However, the literature suggests that referrals for behavioral health and 
prescriptions for smoking cessation treatment were not being consistently 
delivered (Twyman, Bonevski, Paul, and Bryant, 2014).   The literature review 
includes studies that identified the perceived barriers by health care providers to 
the delivery of this treatment and identified factors (i.e. healthcare provider 
characteristics, education) that improved the delivery of the evidence-based 
  
 
smoking cessation treatment (Colomar et al., 2014; Himelhoch, Riddle & 
Goldman, 2014).  And finally, the review of literature includes a summary of 
Kotter’s Theory of Organizational Change.    
A review of the literature was performed using the following databases:  
CINAHL Complete, CINAHL Plus with Full Text, Cochrane Database of 
Systematic Reviews, MEDLINE with Full Text, Psychology and Behavioral 
Sciences Collection, and Google. Keywords used in the literature search included: 
tobacco use, tobacco cessation, primary care, theories of behavior change, health 
professionals.    
Evidence-Based Treatment for Tobacco Use Dependence and Its Delivery    
This section of the literature review will provide a summary of the clinical 
practice guidelines (Fiore, et al., 2008), the recommendations for tobacco smoking 
cessation published by the U.S. Preventive Services Task Force (2015), and the 
American College of Cardiology decision pathway for providing tobacco cessation 
treatment (Barua, R. S. and Rigotti, N. A., et al., (2018).  Studies demonstrating 
the efficacy of behavioral counseling and pharmacotherapy for smoking cessation 
(Fiore et al., 2008, Papakadis et al., 2016, Piper et al, 2018) will be included in the 
review.  The literature review also suggests that primary care providers are 
uniquely positioned to deliver this evidence-based treatment and that the 
interventions recommended result in more successful quit attempts and increased 
smoking abstinence (Fiore et al., 2008).  Studies will be included in the literature 
review that suggests that the evidence-based treatment recommended is not being 
delivered consistently (Twyman, Bonevski, Paul, and Bryant, 2014).     
Clinical Guidelines.  Treating Tobacco Use and Dependence (Fiore, et al., 
2008), was published by the U.S. Department of Health and Human Services, 
providing clinical practice guidelines for tobacco cessation treatment (See 
Appendix B for the 10 key recommendations).   Fiore et al. (2008) strongly suggest 
that effective tobacco interventions require coordinated interventions on the part 
of clinicians, and health care systems and the environment should foster and 
support tobacco intervention as an essential component of healthcare delivery.  
Fiore et al. (2008) also recommend that clinicians should be provided the training 
and support to assist in the delivery of consistent, effective interventions to assist 
their patients in smoking abstinence.  Fiore et al. (2008) conclude that the most 
effective way to get healthcare providers to intervene is to provide them with the 
multiple evidence-based treatment options, provide institutional support for them 
to use those treatments, and create the environment where a failure to intervene is 
not within the standard of care.   
In Chapter 3 Clinical Interventions for Tobacco Use and Dependence 
(Fiore et al., 2008), the guidelines provide the rationale for healthcare providers to 
  
 
make treatment of tobacco use a clinical priority: 1) Clinicians can make a 
difference even with minimal intervention (less than three minutes); 2) there is 
growing evidence that smokers that receive this advice and assistance are reporting 
greater satisfaction with their healthcare, and 3) it is cost-effective.  Fiore et al. 
(2008) recommend the provision of this treatment with the use of the 5A’s and the 
5 R’s Model.  For the patient who is unwilling to quit, Fiore et al. (2008) 
recommend that the clinician use motivational interviewing techniques as 
delineated by the 5 R’s Model: 1) relevance, 2) risks, 3) rewards, 4) roadblocks, 
and 5) repetition.  Fiore et al. (2008) provided evidence that suggested that the use 
of the 5 R’s increases future quit attempts.   
Preventive Services Recommendations for Tobacco Smoking 
Cessation.  In 2015, the United States Preventive Services Task Force published 
the Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral 
and Pharmacotherapy Interventions recommended that healthcare providers 
determine the tobacco status of all adults, advise them to stop using tobacco, and 
provide them with behavioral interventions and the FDA approved 
pharmacotherapy for smoking cessation.  Subsequently, a research plan has been 
developed to study the effectiveness of smoking cessation interventions (USPSTF, 
2018) which may be instrumental in the development of updated treatment 
guidelines (See Appendix E for the recommendations).  
Tobacco Cessation Treatment Decision Tree.   American College of 
Cardiology (ACC) Expert Consensus Decision Pathway on Tobacco Cessation 
Treatment (Barua, R. S. and Rigotti, N. A., et al., (2018) provided a comprehensive 
tobacco cessation treatment decision-making tree with the acknowledgment that 
consistent delivery remains a significant challenge (See Appendix F for the 
decision-making tree).  
Research Suggesting that Combinations of Pharmacotherapy May be 
Effective.  A more recent study (Piper et al., 2018) suggested behavioral health 
interventions and combinations of pharmacotherapy were more effective when 
compared to the usual care (10 minutes of in-person counseling, 8 weeks of a 
nicotine patch, and referral to quitline services) at 4, 8, 16 and 26 weeks to 
abstinence-optimized treatment (3 weeks of pre-quit mini-lozenges, 26 weeks of 
nicotine patch and mini-lozenges, three in-person and eight phone counseling 
sessions and 7-11 automated calls to prompt medication use).  Key outcomes were 
self-reported along with biochemically confirmed 7-day point prevalence.   
 Unique Position to Deliver Tobacco Dependence Treatment.  Primary 
care providers are in a unique position for helping tobacco users. If all primary 
care providers routinely ask about tobacco use and advise tobacco users to stop, 
they have the potential to reach more than 80% of all tobacco users per year; trigger 
40% of cases to make a quit attempt; and help 2-3% of those receiving brief advice 
quit successfully (WHO, 2014).  The research (Fiore et al., 2008) suggests that this 
  
 
brief intervention by healthcare clinicians during a patient’s routine visit can 
provide a cost-effective, and evidence-based treatment for tobacco dependence.    
According to Danesh, Paskett, and Ferketich (2014), healthcare providers in 
primary care can make significant contributions to the reduction of the smoking 
prevalence rates of their patients.  Patients who are advised to quit smoking are 1.6 
times more likely to do so upon the advice of a healthcare provider (Danesh et al, 
2014; Wray, Funderburk, Acker, Wray & Maisto, 2018).   
Lack of Consistent Delivery.  The research suggests that the delivery of 
evidence-based treatment is not occurring consistently (Papadakis, 2016).  
Assisting and arranging for the provision of behavioral health and 
pharmacotherapy for smoking cessation is an essential component of the evidence-
based treatment (Fiore et al., 2008).  According to Kruger et al. (2016), current 
cigarette-only smokers who visited a health professional in the last 12 months self-
reported that only 6.3% had received both counseling and medication for smoking 
cessation within the past year.  Also, Kruger et al. (2016) reported that 3.8% was 
referred to a smoking cessation class or program, 3.7% were referred to one-on-
one counseling and 2.6% were referred to a telephone quitline.  Based upon their 
conclusions, current cigarette-only smokers who reported receiving all 5 A’s 
during a recent clinic visit were more likely to use counseling, medication, or a 
combination of counseling and medication, compared to smokers who received 
one or none of the 5 A’s components.   
With the enactment of the Medicare Access and CHIP Reauthorization Act 
(2015), healthcare providers are now routinely documenting smoking status and 
the provision of advice to quit (CMS, 2018).  However, assistance with and 
arranging for behavioral counseling, medications, programs, and other supports for 
smoking cessation treatment is suboptimal (Roberts et al., 2013; Stead et al., 2016).   
Guidelines for tobacco use dependence are readily available for healthcare 
providers to assist in the provision of evidence-based treatment for smoking 
cessation.  Increasing the number of health care providers that deliver the evidence-
based, brief interventions for tobacco use prescribed by the Public Health Service 
Clinical Practice Guideline will expose more tobacco users to evidence-based 
treatments and will result in more successful quit attempts and tobacco abstinence 
(Fiore et al., 2008, USPSTF, 2014, Barua et al., 2018, Piper et al., 2018).  These 
guidelines and recommendations include the benefits of assistance with and 
arranging for behavioral health and pharmacotherapy for smoking cessation.  
However, the research suggests that is not being done with consistency. Hence, the 
importance of reviewing the literature that identifies the barriers that are perceived 
by healthcare providers that interfere with the successful delivery of this treatment. 
Theoretical Framework    
In the award-winning 8-Step Process for Leading Change (1996), Kotter 
described a methodology that provides a process for implementing successful 
  
 
change in organizations. This 8-Step process is delineated in the following 
paragraphs.  
Creating a sense of urgency.  The first step in the process is creating a 
sense of urgency (Kotter, 2014).  He suggests that people need to see and feel the 
need for change and that your actions and behaviors (not just your words) must 
communicate that need for change.  Without that sense of urgency, he states that 
the change is doomed for failure.  
 Building a guiding coalition.  The second step is building a guiding 
Coalition (Kotter, 1996) in which he suggests that the traditional hierarchical 
structure of most companies cannot quickly adjust to the constantly changing 
environment that can enable it to take advantage of new opportunities or 
challenges.  He recommends that a coalition of effective people within the 
organization guide the changes, coordinate it, and communicate its activities 
(Kotter, 2014).    
Formulate a strategic vision and initiatives.  The third step is to 
formulate a strategic vision and initiatives.  This is important to demonstrate how 
the change is different from the past, and by tying the initiatives directly to the 
vision (Kotter, 2014). 
Enlist a volunteer Army.  The fourth step is to enlist a volunteer army 
because it is only when large numbers of people buy-in and understand the urgency 
to drive change that large-scale change can occur (Kotter, 2014).  Without 
additional volunteer help, the efforts are limited.   
Remove Barriers.  The fifth step is to enable action by removing barriers 
which he states that by removing barriers inefficiencies in the process will provide 
the freedom to work and generate long-lasting impact (Kotter, 2014).   
Enable Short Term Wins.  The sixth step is to enable short term wins by 
recognizing and communicating results early on and often that track progress and 
energizes volunteers to continue persisting (Kotter, 2014).   
Sustain acceleration.  The seventh step is to sustain acceleration by 
pressing harder with the first successful results and being relentless with ongoing 
change until the vision has been realized (Kotter, 2014).   
Institutionalize the Change.  The eight-step in the process is to 
institutionalize the change with the articulation of the connections between the new 
behaviors and the success of the organization and continue until the old habits are 
replaced (Kotter, 2014).   
This 8-step process developed by Kotter (1996, 2014) was used as the 
framework for the development of the design of the study, the educational 
presentation, the development of the quick reference materials provided to the 
healthcare providers, and the dissemination of the results of the study.  Data was 
provided during the educational presentation that demonstrated a 33% smoking 
  
 
prevalence at the FQHC study clinic which is substantially higher than the general 
population.  The international, national, and state targets for reduction in smoking 
prevalence were provided to demonstrate the lack of compliance with those goals 
to create a sense of urgency.  The principal investigator met with administrative 
staff, and incorporated staff responsible for quality improvement to ensure that we 
built a strategic coalition to determine what type of research would be beneficial 
to the FQHC study clinic.   An information technology expert, with specialized 
knowledge in retrieving data and managing the electronic health record at the study 
clinic, was recruited to assist in the project.  Analysis of the documentation of the 
patient’s current smoking status, advice given to quit smoking, and the provision 
of the smoking cessation treatment.  Frequent communication with the information 
technology officer occurred, and initial data was shared with the study clinic 
administrative staff resulting in energizing the individuals involved.  Once the 
results were obtained, and the analysis was completed, communication of the 
information occurred at the monthly provider meeting to provide important 
feedback.       
     
 
Methodology 
Project Description  
 This is a translational research project that was designed to address the need for 
improving the delivery of evidence-based smoking cessation treatment for a 
specific clinical setting within a specific geographical area.  An educational 
intervention was delivered utilizing Kotter’s change theory along with the 
provision of quick reference materials.  In additional several changes were made 
to the electronic health record to provide prompts to support provider 
documentation of smoking status and smoking cessation interventions.   
The purpose of this study was to determine the impact of a multi-component 
intervention on behavioral health referrals for smoking cessation treatment and/or 
the number of prescriptions for smoking cessation pharmacotherapy by healthcare 
providers during visits in five (5) federally qualified healthcare clinic in the 
southeast.   
 
Setting 
The clinics were all located in two separate cities approximately 90 miles 
from a large southeastern metropolitan city.  All clinics were operated by the same 
business entity.  These clinics are designated federally qualified healthcare clinics 
(FQHCs) responsible for the provision of primary healthcare for vulnerable 
  
 
populations for their area.  Sixteen healthcare providers are employed at the clinics 
[4 MD’s, 1 DO, and 11 APRN’s (including part-time APRN who is the PIC for 
this study)].  There is numerous support staff that is tasked with the registration, 
and provision of care during the patient's visit.  Medical Assistants are responsible 
for requesting and entering smoking status information of the patient into the 
electronic healthcare upon arrival and entering verification of the current 
medication list.      
Population and Sample 
The population is healthcare clinicians that provide primary health care at 
FQHCs.  A convenience sample was recruited from the providers at the FQHC 
study clinics located at five different locations. Most providers agreed to 
voluntarily participate.  Even though the primary investigator (PI) was a provider 
at the clinic, there was no participation in the study by the PI.  All participants who 
commenced the study continued to participate until its completion.  
Protection of Human Subjects  
The Georgia College and State University and the Middle Georgia State 
University Institutional Review Board approved this research proposal.  Also, 
approval of the research proposal was sought from the Executive Director and 
Medical Director of the federally qualified healthcare clinic where the study was 
to be conducted.  All participants were given oral and written information about 
the study and provided a consent form to be signed (see Informed Consent as 
Appendix G).   
  The paper surveys collected at the meeting will remain in the possession 
of the PI and will be placed in a locked file cabinet drawer and retained for one 
year.  After one year, the surveys will be shredded to ensure confidentiality and 
discarded securely.    Data files that contain any protected health information will 
be maintained for three years in a password protected electronic file maintained by 
the FQHC study clinic.  Any data will only be reported in the aggregate form for 
any publication or dissemination. Any data file placed on PI’s personal computer 
will be devoid of any patient names or medical record numbers and will also be 
password protected.  If not in the personal possession of the PI, will be maintained 
in a locked cabinet.   
Data Collection Procedures  
 The data collection for this study was completed in three phases using a 
retrospective medical chart review.  An information technology expert 
incorporated the required prompts into the EHR and ran the reports to obtain 
compliance data.  Phase I data collection occurred during the intervention with the 
participant characteristics questionnaire.  Phase II data collection was collected 
immediately following the recruitment of the participants and consisted of a 
retrospective electronic medical chart review of all patients seen by the participants 
  
 
for the period of eight- weeks before the intervention.  Phase III data collection 
was retrieved by a retrospective electronic chart review for all patients seen by 
participants during the eight- weeks following the intervention.  
Smoking Prevalence Rate for FQHC Study Clinic.  Once IRB approval 
was received, aggregate data were retrieved from the FQHC study clinics (5 
clinical practices) electronic health records to determine the total number of adult 
(18 years of age or older) patients seen for 2017 and determine the total number of 
adults who were identified as current smokers for 2017 to ascertain the smoking 
prevalence rate for this FQHC study clinic.       
Phase 1.  Following the educational intervention, all healthcare provider 
participants were asked to complete a demographic questionnaire (See Appendix 
H).  It is estimated that the length of time to complete was approximately 10 
minutes or less.  The additional time for the participants to complete the brief 
interventional counseling and treatment may have added approximately 10 minutes 
to the length of the office visit, which did not excessively burden either the 
healthcare provider participant or the patient during the visit. 
Phase 2.  Following the intervention, data was collected from the EHR for 
all patients seen by each participant to determine the number of patients who were 
candidates to receive the qualifying behavioral and pharmacotherapy smoking 
cessation treatment and the number that received the above for the time eight-
weeks before the intervention.  The percentage of current smokers that received 
the qualifying treatment was calculated by dividing that number by the number of 
patients seen by that provider.  An aggregate percentage for all participants was 
also calculated for this period.  Also, data was collected to determine the number 
of current smokers who were willing to make a quit attempt.       
Phase 3. Upon completion of the Post Intervention period (8 weeks after 
intervention), the same data using the same variables were retrieved from the 
electronic health record for all the participants individually for the eight weeks after 
the intervention. The individual and aggregate percentages were also calculated for 
this period.  The difference in percentages between these two periods was used for 
comparison regarding the delivery of “qualifying treatment” to eligible current 
smokers by healthcare provider participants.  
Intervention  
The multi-component intervention was developed based upon Kotter’s 
theory of individual and organizational change (Kotter, 2014) and the identified 
barriers and factors that impacted the consistent delivery of the evidence-based 
smoking cessation treatment.  The multicomponent intervention was comprised of 
an educational intervention that provided healthcare providers with evidence-based 
smoking cessation treatment, the design, background and methodology of the 
proposed study, quick reference smoking cessation materials, and the 
  
 
programming changes made to the electronic health records to facilitate easy 
documentation for the provision of qualifying behavioral health and 
pharmacotherapy for smoking cessation.   
Educational Intervention.  The purpose of the educational intervention 
was to address identified barriers in published studies (i.e. lack of education and 
training regarding the delivery of smoking cessation treatment, concern about the 
cost of pharmacotherapy, lack of resources, etc.) and based upon Kotter’s steps of 
success in leading change (Kotter, 2014) within organizations (See Appendix I for 
the content delivered at the educational intervention).    
Quick Reference Materials.  Materials were collected, copied and placed 
in a notebook by PI to provide a permanent reference book that could be quickly 
accessed by the participant during a patient’s visit that would refresh their memory 
about the specific data, information, community resources, and where 
documentation will be required to ensure accurate data retrieval for the study (See 
Appendix I for the content included in those notebooks).   
Changes Made to FQHC study clinic electronic health care record.  The 
following changes were made to the EHR to improve the ease of documentation 
for the provision of behavioral health referrals and documentation of 
pharmacotherapy for smoking cessation treatment.  These changes were discussed 
at the provider meeting. 
Instrumentation 
 No instruments were used to obtain data for this study.  Participants 
completed a short demographic questionnaire with questions about race, gender, 
type of provider, years of practice, smoking status, and age group.   
Variables 
Clinical Question 1.  Before-After is a binary variable with the following 
values:  0=Phase II Pre-intervention Period (8 weeks before) and 1= Phase III Post 
Intervention Period (8 weeks after). Candidate is a binary variable created by 
transformation, that indicates if the patient was a candidate for checking to 
determine if they were referred with the following values:  0=No and 1= Yes.  
Compliant is a categorical variable that indicates if the candidate had a referral for 
tobacco cessation treatment (either counseling and/or pharmacotherapy) with the 
following values: 0=No, 1=Yes, and 3=NA-Patient was not a candidate.  
Compliance Percentage is a transformational continuous ratio variable that 
indicates the percentage of compliance by each provider.  
Clinical Question 2. What percentage of Self-Identified Current Smokers 
(SICS) expressed a willingness to attempt quitting? 
  Tobacco Users documented during the visit is a binary (YES/NO) variable 
with the following values: 0=No and 1=Yes.  Quit Interest is a categorical variable 
that indicates the patient’s level of interest in quitting tobacco use with the 
following values:  0=Interest in Quitting not Documented, 1=Not Ready to Quit, 
  
 
2: Not Ready to Quit- found in Progress Notes, 3= Thinking about Quitting, 
4=Thinking about Quitting-found in Progress Notes, 5= Ready to Quit.  The 
previous variables were transformed into a categorical variable Ready or 
Considering Quitting with the following values:  0= Not Ready, 1: Ready to Quit 
or Considering Quitting, 2= Unknown b/c interest not documented.  
 Clinical Question 3. What provider characteristics are associated with 
increased smoking cessation referrals/treatment?     
  Age of Healthcare Participant. A continuous variable that indicates the 
actual age of the participant on the date of the intervention.   
            Type of Provider.  A nominal variable that indicates the type of provider. 
            Race.  This is a nominal variable that indicates the race of the provider.  
            Years of Practice.  A continuous variable that indicates the number of years 
that the provider has been in practice on the date of the intervention.  
           Gender.  A nominal binary variable that indicates the provider’s gender.   
           Smoking Status.  A nominal variable that indicates what the smoking status 
is for the provider. 
          Improvement.   A transformational continuous variable that indicates if 
there is an improvement in the percentage of patients that received the qualifying 
treatment by the healthcare participant (Phase III treatment - Phase II treatment.     
Plan for Data Analysis 
 Following a careful review of the clinical research questions that needed to 
be answered, and determining the study design, a plan for data analysis was 
devised.  Clinical Question #1 is a causal question that seeks information about the 
effect of an intervention on an outcome.  Clinical Question #2 is seeking to 
determine if the percentage of smokers that wish to quit within the FQHC study 
clinic is similar to other national statistics and studies.  Clinical Question #3 is a 
relational question that seeks information about the relationship among variables, 
and whether there is an association between the independent variable and the 
dependent variable. 
 For each variable, the level of measurement will be determined and put into 
SPSS Version 24.  Each of the values associated with that variable will also be 
entered.  Excel files where the original data were downloaded into the SPSS 
Version 24 data file.  Only one individual was responsible for retrieving and 
analyzing the data by a retrospective medical chart review after the algorithms 
were developed to ensure continuity and reduce bias.  Any duplicate files of 
patients seen more than once during the designated period were removed.  A 
determination as to whether the variable is dependent or independent was done.  
For any nominal data, graphic representations were created using pie graphs 
showing frequencies and percentages, and descriptive statistics were run.  For any 
interval or ratio data variables, the descriptive statistics were run to demonstrate 
  
 
the mean, median, and mode, range, percentiles, and levels of skewness and 
kurtosis were run.  A graphic histogram was created to determine if there was a 
normal distribution, and statistical normality tests for small sample sizes were used 
to determine if there was a normal distribution.  Box Plots were also used to 
determine normality, and to determine if there were significant outliers.  Scatter 
Plots were used to determine if there were any associations between the healthcare 
participant characteristics (i.e. age, years of practice, gender, smoking status) and 
the Improvement variable.  For Clinical Question #1, descriptive statistics will be 
used to describe the Difference continuous variable (Post-Intervention Percentage 
– Pre-Intervention Percentage).  In addition to the above, inferential statistics that 
will be used is the Wilcoxon Ranked Test, if the results are non-parametric for the 
paired sample testing. 
For Clinical Question #2, simple descriptive statistics will be run to 
determine the percentage of current smokers that wish to quit. 
For Clinical Question #3, descriptive statistics will be used for all 
independent and dependent variables.  As stated above graphics will be used to 
demonstrate the percentages in the form of pie graphs and histograms.  For any 
variables that are normally distributed, parametric inferential testing will be done 
by Pearson’s Correlation.  For the non-parametric testing required secondary to 
lack of normality, Spearman’s Rho will be utilized for binomial variables and 
ordinal variables.  When correlating nominal categorical variables with continuous 
ratio variables, chi-square analysis will be performed using SPSS Version 24 for 
all the above.   
TimeLine 
 The timeline for this study commenced after IRB approval.  Phase 1 began 
with the educational intervention and the recruitment of the participants.  Phase 2 
started following the educational intervention and retrospectively collected data 
for 8 weeks before the intervention.  Phase 3 commenced 8 weeks post-
intervention, and retrospectively collected data from the intervention until 8 weeks 
post-intervention.    
Budget 
 The monetary cost for this project is estimated to be $300.00 for printing 
costs of the quick reference materials, and printing of dissemination materials.  The 
federally qualified healthcare clinic sponsored the costs of notebooks used for the 
quick reference materials, and the costs of utilizing a programmer to retrieve 
electronic health data.  The APRN completing the intervention donated time for 
preparing and delivering the educational intervention and preparation of the quick 




The project, setting, and population to be studied have been described in 
detail.  The protection of human subjects and the data to be collected has been 
provided.  All data collection procedures have been delineated for all phases of the 
study.  The multicomponent intervention has been described to provide an 
overview of the content.  The variables subject to statistical testing have been given 
for each clinical question.  The plan for data analysis using SPSS Version 24 has 
been described, as well as the budget and timeline for the translational clinical 
project.     
Results 
The healthcare participants were recruited using convenience sampling.  Data was 
gathered by retrospective medical record review after participants were recruited 
to collect for pre-intervention and post-intervention data.  SPSS Version 24 (IBM, 
2016) was used to calculate the statistical results of this study.  
Clinical Question 1.  How does education about smoking cessation and the 
provision of quick reference materials affect referrals to behavioral 
counseling and prescribing smoking cessation pharmacotherapy with 
healthcare providers at federally qualified healthcare centers in one 
southeastern state within an eight-week period?  The Wilcoxon Rank test was 
run since the data was not normally distributed.  A comparison of the pre-
intervention compliance and post-intervention compliance showed an 
improvement of 11% (Z=-2.09, p=.037).  Health care providers improved in their 
referrals of patients for smoking cessation treatment.        
Clinical Question 2. What percentage of Self-Identified Current 
Smokers (SICS) expressed a willingness to attempt quitting?  Descriptive 
statistics were run to determine the percentage of current smokers that have 
expressed a willingness to attempt quitting during the Post Intervention Period.  
Out of the identified tobacco users, 254 (61%) individuals were identified as 
interested in or thinking about quitting.  These results are similar to the Center for 
Disease Control (2018) statistics (70%) who have expressed a desire to quit. 
Clinical Question 3. What provider characteristics are associated with 
increased smoking cessation referrals/treatment?  
Age Variable.  Spearman’s Rank-Order Correlation was run since the data 
for age and improvement were not normally distributed.  Data indicated that the 
clinical question as to whether age and improvement were positively correlated 
was not supported.  There was no significant positive correlation between age and 
improvement (r=.042, p=.891).   
Years of Practice.  Spearman’s Rank-Order Correlation analysis was run 
since the data for the variable of years of practice and improvement were not 
normally distributed.  Data indicated that clinical question as to whether years of 
practice and improvement were positively correlated was not supported.  There 
  
 
was no significant positive correlation between years of practice and improvement 
(r=.127, p=.891).  
Gender Variable.  Spearman’s Rank-Order Correlation analysis was run 
since the data for the variable of gender (binomial) and improvement was not 
normally distributed.  Data indicated that clinical question as to whether gender 
and improvement were positively correlated was not supported.  There was no 
significant positive correlation between gender and improvement (r⸈=.058, 
p=.851).   
Race variable.  Pearson’s Chi-square analysis was run used to test the 
clinical question as to whether race and improvement were positively correlated.  
There was no significant correlation between race and improvement (X2 .853, df 
(2), p=.653).   
Type of Provider.   Pearson’s Chi-square analysis was run to test the 
clinical question as to whether the type of provider and improvement were 
positively correlated.  There was no significant positive correlation between the 
type of provider and improvement (X2=(3.494, df=2, p=.174).         
Smoking Status.  Pearson’s Chi-Square analysis was run to test the clinical 
question as to whether the smoking status of the provider and improvement were 
positively correlated.  There was no significant positive correlation between 
smoking status and improvement (X2=1.477, df=1, p=.224).  It should be noted 
that the sample did not include any current smokers, so the reliability of these 
statistical results could be called into question.     
As it relates to Clinical Question #1, 17.4% of all “eligible” candidates 
received the “qualifying treatment” during the pre-intervention period.  Following 
the implementation of the intervention, 28.96% of all “eligible” candidates 
received the “qualifying treatment”.  This resulted in 34 more patients or an 11% 
(Z=-2.09, p=.037) increase in the number of patients who have received the 
“qualifying treatment” during the post-intervention period.    The result for Clinical 
Question #2 showed that the patients at the FQHC study clinic wished to quit 
smoking at a similar rate to the national statistics produced by the CDC (2018).  
The result for Clinical Question #3 showed no statistically significant positive 
correlation for any of the healthcare provider characteristics to improvement in the 






  The small size of the sample (n=13) and the necessity of using a 
convenience sampling method reduced the ability to generalize the results of this 
study (Kellar and Kelvin, 2013).  The outcome dependent variable measuring the 
difference in compliance with the provision of the “qualifying treatment” was 
measured after 8 weeks secondary to the time limitations for an academic 
translational project.  The study could have been improved by examining the long-
term effect of the multi-component intervention and the sustainability of the effect 
of the interventions by measuring the level of compliance after 6 months.  Because 
the study only studied the impact on the healthcare provider in the delivery of the 
smoking cessation treatment and not the impact on the patient’s smoking 
abstinence, it did not result in the ability to determine the causal effect of the 
delivery of the smoking cessation treatment.   Another limitation of this study is 
that during the intervention, instructions were given to where the documentation 
of compliance should be entered into the electronic health record to optimize the 
collection of that data.  Since no instructions had been given before the 
documentation during the pre-intervention period it may have resulted in a 
decreased documentation of that delivery of that treatment.     
One other factor that may have influenced the outcome of this study was 
the lack of incorporation of physicians in the presentation of the educational 
information.  It might have provided some additional credibility to the information 
from the perspective of other physician providers.     
As the quick reference materials were being developed, the difficulty in 
locating community resources for both behavioral health for smoking cessation 
and smoking cessation classes became evident.  It would have been more helpful 
to have discovered these resources in our community, or at least been able to 
ascertain those resources in neighboring communities.  
Some data collection issues became evident following some investigation.  
It was determined that not every medical assistant refreshed the data with each visit 
regarding smoking status.  Rather than simply addressing the demographic and 
practice characteristics in the participant survey, it would have been more helpful 
to develop a validated and reliable survey tool for the healthcare providers that 
could determine their level of self-efficacy before and after the intervention.   
Strengths 
  The strengths of this study include the fact that nearly all healthcare 
providers voluntarily engaged as participants in the study without any attrition.  
This demonstrated their interest in being a part of a quality improvement project 




As an extension of the current research, determine whether the statistically 
significant impact of the educational training and the use of the reference materials 
on the healthcare providers could be retained at six months.  Research for the future 
should focus on the impact of the use of interventions using web site applications 
and text messaging for smoking cessation.       
Summary  
This translational clinical project provided answers to the clinical questions 
studied.   The data collected and analyzed for Clinical Question #1 during Phase II 
(pre-intervention) and Phase III (post-intervention) demonstrated a statistically 
significant (Z=-2.09, p=.037)                  increase in compliance (provision of 
“qualifying treatment” to “eligible” patients) following the multicomponent 
intervention. A comparison of the pre-intervention compliance and post-
intervention compliance showed an improvement of 11%.        
The data collected and analyzed for Clinical Question #2 during Phase III 
(post-intervention) demonstrated that the current smokers at the FQHC study clinic 
wished to quit smoking (61%).  According to national statistics generated by the 
CDC (2017), approximately 70% of current smokers wished to quit.  These results 
demonstrate that the desire to quit at the FQHC study clinic is similar to national 
data.   
The data collected and analyzed for Clinical Question #3 during Phase One 
from the Healthcare Provider Survey (i.e. age, years of practice, race, provider 
type, smoking status) was determined to have no positive correlation to the 




Significant progress has been made in the reduction of tobacco use in the United 
States, but the smoking prevalence among the socially and economically 
disadvantaged populations (i.e. individuals who are homeless, uninsured, LGBT, 
and living with HIV) is significantly higher than the general population (CDC, 
2018b).  This results in this population carrying a disproportionate burden of 
tobacco-related mortality and morbidity (CDC, 2018b).  There is a cost-effective 
and evidence-based treatment for tobacco use dependence (Fiore et al, 2008), but 
the delivery by primary care providers to this population (Tyman, Bonevski, Paul, 
and Bryant, 2014) is inconsistent.  The study focused on determining whether the 
delivery of a multicomponent intervention (i.e. educational session, quick 
reference materials, and prompts in the electronic health records) to the health care 
providers (n=13) at a federally qualified health care clinic would result in an 
improvement of behavioral health referrals and pharmacotherapy for smoking 
cessation.  A retrospective review of the 8 weeks before the intervention, and 8 
  
 
weeks after the intervention, was conducted to examine changes in provider 
compliance with smoking cessation treatment guidelines.   The data collected 
suggested that there was a statistically significant increase in compliance with the 
delivery of the qualifying treatment (Z=-2.09, p=.037) following the intervention.  
The study also examined the relationship between demographic characteristics of 
providers and improvement in provider compliance with no significant positive 
correlations.  Additional research is needed to examine whether this improvement 
in compliance can be sustained at six months.        
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Appendix A 
   Fact sheet about the health benefits of smoking 
cessation 
1. There are immediate and long-term health benefits of quitting for all 
smokers. 
 
Beneficial health changes that take place: 
a. Within 20 minutes, your heart rate and blood pressure drop. 
b. 12 hours, the carbon monoxide level in your blood drops to normal. 
c. 2-12 weeks, your circulation improves and your lung function increases. 
  
 
d. 1-9 months, coughing, and shortness of breath decrease. 
e. 1 year, your risk of coronary heart disease is about half that of a smoker's. 
f. 5 years, your stroke risk is reduced to that of a nonsmoker 5 to 15 years after quitting. 
g. 10 years, your risk of lung cancer falls to about half that of a smoker, and your risk of 
cancer of the mouth, throat, esophagus, bladder, cervix, and pancreas decreases. 
h. 15 years, the risk of coronary heart disease is that of non-smokers.  
 
2. People of all ages who have already developed smoking-related health 
problems can still benefit from quitting. 
Benefits in comparison with those who continued: 
a. At about 30: gain almost 10 years of life expectancy. 
b. At about 40: gain 9 years of life expectancy. 
c. At about 50: gain 6 years of life expectancy. 
d. At about 60: gain 3 years of life expectancy. 
After the onset of life-threatening disease: rapid benefit, people who quit smoking after having 
a heart attack reduce their chances of having another heart attack by 50% 
3. Quitting smoking decreases the excess risk of many diseases related to 
second-hand smoke in children. 
Quitting smoking decreases the excess risk of many diseases related to second-hand smoke in 
children, such as respiratory diseases (e.g., asthma) and ear infections. 
 
4. Others benefits. 
Quitting smoking reduces the chances of impotence, having difficulty getting pregnant, having 
premature births, babies with low birth weights and miscarriage. 
 
Source:  World Health Organization. (2014).  Toolkit for Delivering the 5A’s and 5 R’s brief 
tobacco intervention in primary care. Geneva, Switzerland; WHO Press.  Retrieved from 
https://apps.who.int/iris/bitstream/handle/10665/112835/9789241506953_eng.pdf;jsessionid=
7A3E873BD2237654BF8EF8EAD67425B1?sequence=1World Health Organization (2014.)   
Appendix B 
10 Key Recommendations  
1. Tobacco dependence may require repetitive interventions, and 
multiple quit attempts by smokers to accomplish smoking cessation.  
The research supports that effective treatments are in existence and 
they can improve the success rate of long-term smoking abstinence;  
2. It is imperative that clinicians consistently identify tobacco use status 
and then treat every tobacco user seen in their health setting;  
  
 
3. Tobacco cessation treatments are effective for most populations.  
Healthcare providers should assist every patient willing to make a quit 
attempt to use the behavioral/counseling treatments and smoking 
cessation medications that are recommended by this guideline;   
4. Brief tobacco dependence treatment can be effective and should be 
offered as a minimum;   
5. Individual, group and telephone behavioral health counseling are 
effective, and the more intense the treatment the more effective;   
6. Numerous medications are available for treatment for tobacco 
dependence; Clinicians should encourage the use of these medications 
for all patients attempting to quit smoking, unless medically 
contraindicated or where there is insufficient evidence of 
effectiveness.  The medications recommended that are proven to 
increase long-term smoking abstinence:  Bupropion SR, Nicotine 
gum, nicotine inhaler, nicotine lozenge, nicotine nasal spray, nicotine 
patch, and varenicline.  They also recommended that certain 
combinations can be effective with certain populations;  
7. Counseling for smoking cessation and medications are effective either 
by themselves.  The most effective treatment is the combination of 
counseling and smoking cessation pharmacotherapy.  As clinicians we 
should encourage all making a quit attempt to use both;   
8. Telephone quitline counseling is effective with many different 
population groups, and healthcare providers should ensure that 
patients should have access to quitlines and promote its use;   
9. If a current smoker of tobacco is unwilling to make a quit attempt 
upon being advised to quit, the healthcare providers should use the 
evidence-based motivational treatment to increase future quit 
attempts;   
10. The recommended treatment is effective and cost-effective and 
recommended that insurance plans should ensure that the counseling 
and smoking cessation pharmacotherapy recommended is a covered 
benefit. 
Source:  Fiore, M.C. Jaen, C. R., Baker, T.B. et al.  (2008). Treating Tobacco Use 
and Dependence: 2008 Update.  Clinical Practice Guideline. Rockville, 
MD:  U.S. Department of Health and Human Services.  Public Health 




World Health Organization 5A’s Model for Individuals Motivated to Quit 
  
 
5A’s Action Strategies for implementation 
Ask -  
Systematically 
identify all 
tobacco users at 
every visit. 
• Ask ALL your patients at 
every encounter if they 
use tobacco and 
document it.  
• Make it part of your 
routine. 
• Tobacco use should be asked about in a friendly way – 
it is not an accusation.  
• Keep it simple, some sample questions may include:  
– “Do you smoke cigarettes?” 
– “Do you use any tobacco products?” 
• Tobacco use status should be included in all medical 
notes. Countries should consider expanding the vital 
signs to include tobacco use or using tobacco use status 
stickers on all patient charts or indicating tobacco use 




that they need 
to quit 
• Urge every tobacco user to 
quit in a clear, strong and 
personalized manner.  
Advice should be: 
• Clear – “It is important that you quit smoking (or using 
chewing tobacco) now, and I can help you.” “Cutting down 
while you are ill is not enough.” 
“Occasional or light smoking is still dangerous.” 
• Strong – “As your doctor, I need you to know that quitting 
smoking is the most important thing you can do to protect 
your health now and in the future. We are here to help 
you.” 
• Personalized – Tie tobacco use to: 
− Demographics: For example, women may be more likely 
to be interested in the effects of smoking on fertility than 
men. 
− Health concerns: Asthma sufferers may need to hear 
about the effect of smoking on respiratory function, 
while those with gum disease may be interested in the 
effects of smoking on oral health. “Continuing to smoke 
makes your asthma worse, and quitting may 
dramatically improve your health.” 
− Social factors: People with young children may be 
motivated by information on the effects of second-hand 
smoke, while a person struggling with money may want 
to consider the financial costs of smoking. “Quitting 
smoking may reduce the number of ear infections your 
child has.” 
In some cases, how to tailor advice for a particular patient 
may not always be obvious. A useful strategy may be to 
ask the patient: − “What do you not like about being a 
smoker?” 
The patient’s answer to this question can be built upon by 
you with more detailed information on the issue raised. 
− Example: 
Doctor: “What do you not like about being a smoker?” 
Patient: “Well, I don’t like how much I spend on tobacco.” 
Doctor: “Yes, it does build up. Let’s work out how much 
you spend each month. Then we can think about what 






make a quit 
attempt 
Ask two questions in relation 
to “importance” and “self-
efficacy”: 
1. “Would you like to be a 
nontobacco user?” 
“Do you think you have a 
chance of quitting 
successfully?” 
Any answer to either question that is Unsure or No indicates 
that the tobacco user is NOT ready to quit. In these cases, 
you should deliver the 5 R’s intervention. 
Question 1 Unsure No 
Question 2 Unsure No 
 
If the patient is ready to go ahead with a quit attempt you 
can move onto Assist and Arrange steps. 
  
 
Assist - Help 
the patient with 
a quit plan 
• Help the patient develop a 
quit plan  
• Provide practical 
counseling  
• Provide intra-treatment 
social support 
• Provide supplementary 
materials, including 
information on quitlines 
and other referral 
resources 
Recommend the use of 
approved medication if 
needed 
•Use the STAR method to facilitate and help your patient to 
develop a quit plan:  
− Set a quit date ideally within two weeks. 
− Tell family, friends, and coworkers about quitting, and ask 
for support. 
− Anticipate challenges to the upcoming quit attempt.  
− Remove tobacco products from the patient’s environment 
and make the home smoke free. 
•Practical counseling should focus on three elements: 
− Help the patient identify the danger situations (events, 
internal states, or activities that increase the risk of smoking 
or relapse). 
− Help the patient identify and practice cognitive and 
behavioral coping skills to address dangerous situations. 
− Provide basic information about smoking and quitting 
•Intra-treatment social support includes: 
− Encourage the patient in the quit attempt 
− Communicate caring and concern 
− Encourage the patient to talk about the quitting process 
•Make sure you have a list of existing local tobacco 
cessation services (quitlines, tobacco cessation clinics, and 
others) on hand for providing information whenever the 
patient inquiries about them. 
•The support given to the patient needs to be described 












Arrange - Schedule follow-
up contacts or a referral to 
specialist support 
When: The first follow up contact should be arranged during 
the first week. A second follow up contact is recommended 
within one month after the quit date.  
•How: Use practical methods such as telephone, personal 
visit and mail/ email to do the follow-up. Following up with 
patients is recommended to be done through teamwork if 
possible.  
•What: 
For all patients: 
− Identify problems already encountered and anticipate 
challenges.  
− Remind patients of available extra-treatment social 
support. 
− Assess medication use and problems. − Schedule the 
next follow up contact. 
For abstinent patients: 
− Congratulate them on their success. 
For patients who have used tobacco again: 
− Remind them to view relapse as a learning experience.  
− Review circumstances and elicit recommitment.  
− Link to more intensive treatment if available. 
 
Source:  World Health Organization. (2014).  Toolkit for Delivering the 5A’s and 
5 R’s brief tobacco intervention in primary care. Geneva, Switzerland; WHO 
Press.  Retrieved from 
https://apps.who.int/iris/bitstream/handle/10665/112835/9789241506953_eng.pd








World Health Organization 5R’s Model for Individuals Not Motivated to 
Quit 
 
5R’s Strategies for implementation Example 
Relevance Encourage the patient to indicate how quitting is 
personally relevant to him or her. 
Motivational information has the greatest impact if it 
is relevant to a patient’s disease status or risk, 
family or social situation (e.g. having children in the 
home), health concerns, age, sex, and other 
important patient characteristics (e.g. prior quitting 
experience, personal barriers to cessation). 
HCP: “How is quitting most personally 
relevant to you?” 
P: “I suppose smoking is bad for my 
health.” 
Risks Encourage the patient to identify potential negative 
consequences of tobacco use that are relevant to 
him or her. 
Examples of risks are: 
• Acute risks: shortness of breath, 
exacerbation of asthma, increased risk of 
respiratory infections, harm to pregnancy, 
impotence, and infertility. 
• Long-term risks: heart attacks and 
strokes, lung and other cancers (e.g. larynx, oral 
cavity, pharynx, esophagus), chronic obstructive 
pulmonary diseases, osteoporosis, long-term 
disability, and need for extended care. 
• Environmental risks: increased risk of 
lung cancer and heart disease in spouses; 
increased risk for low birth-weight, sudden infant 
death syndrome, asthma, middle ear disease, 
and respiratory infections in children of smokers. 
HCP: “What do you know about the risks 
of smoking to your health? What 
particularly worries you?” ¨ 
P: “I know it causes cancer. That must be 
awful.” 
HCP: “That’s right – the risk of cancer is 
many times higher among smokers.” 
Rewards Ask the patient to identify potentially relevant 
benefits of stopping tobacco use.  
Examples of rewards could include: 
− improved health; 
− food will taste better; 
− improved sense of smell; 
− saving money; 
− feeling better about oneself; 
− home, car, clothing, and breath will smell better; 
− setting a good example for children and 
decreasing the likelihood that they will smoke; 
− having healthier babies and children; 
− feeling better physically; 
− performing better in physical activities. 
− improved appearance, including reduced 
wrinkling/aging of the skin and whiter teeth. 
HCP: “Do you know how stopping 
smoking would affect your risk of cancer?” 
P: “I guess it would be more successful if I 
quit.” 
HCP: “Yes, and it doesn’t take long for the 
risk to decrease. But it’s important to quit as 




Source:  World Health Organization. (2014).  Toolkit for Delivering the 5A’s and 
5 R’s brief tobacco intervention in primary care. Geneva, Switzerland; WHO 









The USPSTF recommends that clinicians ask all 
adults about tobacco use, advise them to stop using 
tobacco, and provide behavioral interventions and the 
U.S. Food and Drug Administration (FDA)-approved 






The USPSTF recommends that clinicians ask all 
pregnant women about tobacco use, advise them to 
stop using tobacco, and provide behavioral 






The USPSTF concludes that the current evidence is 
insufficient to assess the balance of benefits and 
harms of pharmacotherapy interventions for tobacco 







The USPSTF concludes that the current evidence is 
insufficient to recommend electronic nicotine delivery 
systems (ENDS) for tobacco cessation in adults, 
including pregnant women. 
 
I 
Source:  U.S. Preventive Services Task Force.  (2015).  Final Update Summary: 
Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral 
and Pharmacotherapy Interventions. U.S. Preventive Services Task Force. 












Consensus Decision Pathway on Tobacco Cessation Treatment 
 
Source:  Barua, R. S. and Rigotti, N. A., et al., (2018).  ACC expert 









I, _________________________________________________, agree to 
participate in the research “Effect of an Intervention to Improve Smoking 
Cessation treatment in a Federally Qualified Healthcare Clinic”, which is being 
conducted by Shirley A. Camp, JD, MSN, FNP-C, who can be reached at (478) 
471-2979 or shirley.camp@bobcats.gcsu.edu. I understand that my participation 
is voluntary; I can withdraw my consent at any time. If I withdraw my consent, 
my data will not be used as part of the study and will be destroyed. 
 
The following points have been explained to me: 
 
1. The purpose of this study is an interdisciplinary effort to increase 
access to smoking cessation treatment for the underserved population 
at XXXXXXXXXXXXX with the provision of a smoking cessation 
treatment educational intervention that is individualized for a federally 
qualified healthcare clinic population.  In addition, participants will be 
provided with quick reference materials that will provide information 
about behavioral healthcare community resources for smoking 
cessation and the efficacy and cost of smoking cessation 
pharmacotherapy.   
2. The procedures are as follows: you will be asked to listen to an 
educational intervention conducted by the principal investigator and 
complete a simple demographic and practice survey.  Once you have 
agreed to participate and signed the informed consent, data will be 
retrieved from the electronic health record of any patient that you have 
seen and treated in the previous eight (8) weeks who are self-identified 
smokers.  The determination will be made if they indicated a 
willingness to quit smoking, and if so, whether they were referred to 
behavioral counseling (including the Georgia Smoking Quitline) or 
given prescriptions for smoking cessation pharmacotherapy.  
Following the educational intervention, the healthcare provider will be 
expected to implement the recommended treatment and documentation 
for smoking cessation treatment for all patients that express an interest 
in quitting tobacco use.  For a period of eight (8) weeks following the 
educational intervention, the same data will be collected to determine 
if there has been an increase in the percentage of behavioral health 
referrals and/or smoking cessation pharmacotherapy prescriptions.       
  
 
3. Your name will be connected to your demographic/practice survey but 
will be secured and maintained in the sole possession of the Principal 
Investigator.  Following one year, the survey will be confidentially 
destroyed.  Two reports will be generated for the PI per participant by 
the computer technician with the aggregate patient data.  No patient 
names or nor patient medical record numbers will be provided to PI.  
No FCPC administration will have access to any of this provider-
specific information.  Any dissemination of this information for 
publication will be provided only in the aggregate and without mention 
of provider names or patient names.  Any patient files will be 
protected by a password-protected file, and a laptop which is placed in 
a locked secure location, unless in the immediate presence of the 
principal investigator.    
4. You will be asked to sign two identical consent forms. You must 
return one form to the investigator before the study begins, and you 
may keep the other consent form for your records. 
5. You may find that some questions are invasive or personal. If you 
become uncomfortable answering any questions, you may cease 
participation at that time. 
6. This research project is being conducted because of its potential 
benefits, either to individuals or to humans in general. The expected 
benefits of this study include 1) improving your understanding of the 
most recent evidence-based smoking cessation treatment that is 
individualized for the patient population that is treated at a federally 
qualified healthcare clinic; 2) improving the percentage of self-
identified patients that are referred to behavioral counseling for 
smoking cessation; 3) improving the percentage of patients who are 
self-identified smokers (SIS) that receive smoking cessation 
pharmacotherapy (if eligible). Because of the established effectiveness 
of these two interventions, the resulting increase in smoking quit rates, 
and abstinence has a substantial economic and health outcomes effect.   
7. You are not likely to experience physical, psychological, social, or 
legal risks beyond those ordinarily encountered in daily life or during 
the performance of routine examinations or tests by participating in 
this study. 
8. Your responses will be confidential and will not be released in any 
individually identifiable form without your prior consent unless 
required by law. 
9. The investigator will answer any further questions about the research 




10. In addition to the above, further information, including a full 
explanation of the purpose of this research, will be provided after the 
research project has been completed on request. 
11. By signing and returning this form, you are acknowledging that you 
are 18 years of age or older.   
 
 
Signature of Investigator Date 
 
 
Signature of Participant Date 
 
 
Research at Georgia College involving human participants is carried out under the 
oversight of the Institutional Review Board. Address questions or problems 
regarding these activities to Dr. Whitney Heppner, GC IRB Chair, CBX 090, GC, 







Effect of an Intervention to Improve Smoking Cessation 
Treatment in a Federally Qualified Healthcare Clinic 
Healthcare Provider Participant Survey (Phase I) 
 
Participant Name    ______________________________________                            
   Last Name   First Name 
 






















70 or above 
 
















Years of Practice (Circle appropriate answer) 
  
0-2 years of practice 
 
 3-5 years of practice 
 
 6-10 years of practice 
 
 11-19 years of practice 
 













After this data was received, the participants were contacted and requested that they 
provide their actual age and the years of practice on July 25, 2018, for more 




Effect of an Intervention to Improve Smoking Cessation Treatment in a 
Federally Qualified Healthcare Clinic  
Educational Program for Healthcare Providers 
 
Identification of the Problem 
 Smoking Prevalence Rate at FQHC Study Clinic 
International, National and State Goals for Tobacco Control 
Primary Care Providers Delivery 
Study Design 
Clinical Questions  
Purpose of the Study  
Participation in Study  
Background information  
Health Risks and Economic Costs Associated with Tobacco Use 
Benefits of tobacco cessation 
Prevalence among Vulnerable populations  
Literature Review 
Clinical Guidelines for Tobacco Use Dependence Treatment 
 Key Recommendations 
Review of 5 A’s ad 5 R’s Model 
USPSTF Recommendations for Tobacco Use Treatment  
American College of Cardiology Decision Tree 




Identification of Barriers and Factors in Delivery of Smoking 
Cessation Treatment 
Presentation by Executive Director for Georgia Smoking Quit Line 
Presentation by Director of Community Smoking Cessation Classes 
Required EHR Documentation to Determine Compliance for Study 
Qualified Behavioral Health Referrals and Pharmacotherapy 
for Smoking Cessation Treatment 
 Review of Quick Reference Materials 
Copy of Clinical Guidelines for Tobacco Use Dependence 
Efficacy, Issues, and Costs Associated with Smoking Cessation 
Pharmacotherapy  
Insurance Coverage/Costs Associated with Behavioral Health 
Referrals and Pharmacotherapy for Smoking Cessation  
Impact of the Patient Care and Affordability Care Act 
(2010)  
Available Coupons for Smoking Cessation 
Pharmacotherapy     
 
 
